New trial aims to boost survival in kidney cancer by combining radiation with drug therapy
NCT ID NCT06726421
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase III trial is testing whether adding a precise type of radiation (SBRT) to standard drug therapy (targeted drugs and/or immunotherapy) can help people with kidney cancer that has spread to up to five spots live longer without the disease getting worse. The study will enroll 252 participants and compare the combination approach to drug therapy alone. Researchers will also track side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiotherapy (SBRT) plus standard systemic therapy (targeted drugs and/or immunotherapy)
What this could lead to
If it works, this could show that adding precise radiation to standard drugs helps people with limited kidney cancer spread live longer without progression.
What could go wrong
This is an early-stage Phase III trial with 252 participants, so results may not apply to everyone. Adding radiation may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (KIDNEY CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking University First Hospital
RECRUITINGBeijing, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Fujian Medical University
RECRUITINGFuzhou, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact